Releases

SER=Stock exchange releasePR=Press release

Select year: 
17/12/2014 SER Issue of new treasury shares of Biotie Therapies Corp without consideration and cancellation of shares held by Biotie Therapies AG
17/12/2014 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
26/11/2014 SER BIOTIE: UK'S NICE ISSUES POSITIVE FINAL GUIDANCE FOR SELINCRO®
31/10/2014 SER Biotie interim report 1 January - 30 September 2014
29/09/2014 SER Biotie's Financial Information in 2015
19/09/2014 SER Biotie: Selincro enters the market in France
29/08/2014 SER Biotie: Selincro enters the market in Germany
28/08/2014 SER Biotie: Formal transfer of global rights for tozadenant to Biotie concluded
21/08/2014 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
21/08/2014 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
01/08/2014 SER Correction to Biotie Therapies Corp. interim report for January - June 2014
01/08/2014 SER Correction to Stock Exchange Release: Change in the number of votes relating to Biotie Therapies Corp.'s shares published 30 July at 8.45 am
30/07/2014 SER Biotie interim report 1 January - 30 June 2014
30/07/2014 SER Biotie updates outlook on tozadenant and SYN120
30/07/2014 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
30/07/2014 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
24/07/2014 SER Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding
22/07/2014 SER Biotie: Selincro enters the market in Spain
11/07/2014 SER Biotie decides not to exercise option to acquire Neurelis, Inc. but retains economic interest in future success of NRL-1
10/07/2014 SER Biotie: Selincro receives positive draft guidance from UK's NICE
08/07/2014 SER Biotie: Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology
08/07/2014 SER Biotie awarded USD 2 million grant from The Michael J. Fox Foundation for a clinical study with SYN120 in Parkinson's Disease Dementia
03/06/2014 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
27/05/2014 SER Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014
09/05/2014 SER Biotie: Change in the number of votes
09/05/2014 SER Biotie interim report 1 January - 31 March 2014
06/05/2014 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
03/04/2014 SER Biotie: Change in the number of votes
03/04/2014 SER RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD
21/03/2014 SER Biotie to regain global rights to tozadenant from UCB
04/03/2014 SER Biotie's Financial Statement Report and Corporate Governance Statement 2013 published
28/02/2014 SER INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
28/02/2014 SER Biotie Financial Statement Release 2013
28/02/2014 SER Biotie updates outlook: Intends to develop SYN120 internally and will not exercise its option to acquire Neurelis until further notice
28/02/2014 SER Biotie: Change in the number of votes
28/01/2014 SER Biotie: Change in the number of votes
08/01/2014 SER New Treasury Shares of Biotie Therapies Corp registered with the Trade Register
03/01/2014 SER The Board of Directors of Biotie Therapies Corp. has Approved Three Year Incentive Plans for Employees
03/01/2014 SER Issue of new treasury shares of Biotie Therapies Corp without consideration
03/01/2014 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
21/11/2013 SER Biotie's loan obligations to Tekes reduced by EUR 2.8 million
14/11/2013 SER Biotie: Notification according to Chapter 9, Section 10 of the Finnish Securities Market Act
06/11/2013 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
01/11/2013 SER Biotie interim report 1 January - 30 September 2013
31/10/2013 SER Biotie: Lundbeck and Otsuka announce partnership to develop and commercialize nalmefene in Japan
07/10/2013 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
07/10/2013 SER Biotie's Financial Information in 2014
26/09/2013 SER Biotie: Selincro enters the market in Italy
24/09/2013 SER Biotie Completes Planned Portfolio Review
04/09/2013 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
02/08/2013 SER Biotie interim report 1 January - 30 June 2013
04/06/2013 SER Biotie purchases option to acquire Neurelis, Inc.
10/05/2013 SER Biotie announces start of clinical study with nepicastat (SYN117) in cocaine dependence
06/05/2013 SER Biotie: Selincro launched in the United Kingdom
06/05/2013 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
03/05/2013 SER Biotie interim report 1 January - 31 March 2013
22/04/2013 SER Biotie: Selincro launched in first European markets
04/04/2013 SER RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD
21/03/2013 SER Biotie Presents Tozadenant Phase 2b data at AAN Annual Meeting
07/03/2013 SER Biotie's Annual Financial Report and Corporate Governance Statement 2012 published
04/03/2013 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
28/02/2013 SER Biotie: Selincro (nalmefene) receives European marketing authorization
28/02/2013 SER INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
28/02/2013 SER Biotie financial statement report 1 January - 31 December 2012
28/02/2013 SER Biotie updates outlook - non-cash impairment charge for ronomilast
27/02/2013 SER Amendment to the release on UCB license of worldwide rights to tozadenant in Parkinson's disease from Biotie
26/02/2013 SER Biotie: UCB to license worldwide rights to tozadenant in Parkinson's disease from Biotie
04/02/2013 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
03/01/2013 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
02/01/2013 SER David Cook appointed Chief Financial Officer of Biotie
27/12/2012 SER Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress disorder
14/12/2012 SER Biotie: Selincro(TM) (nalmefene) receives positive opinion for approval in the European Union
11/12/2012 SER Biotie's tozadenant (SYN115) meets primary and multiple secondary endpoints in phase 2b study in Parkinson's disease
03/12/2012 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
02/11/2012 SER Biotie Interim report 1 January - 30 September 2012
02/11/2012 SER Biotie's Financial Information in 2013
02/10/2012 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
17/09/2012 SER Change in Biotie management
17/09/2012 SER New Biotie shares and increase of share capital registered with the Finnish Trade Register
07/09/2012 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
07/09/2012 SER A listing prospectus concerning listing of new shares in Biotie has been published
07/09/2012 SER Biotie has completed a directed share issue of EUR 20 million to institutional and strategic investors
07/09/2012 SER Lundbeck has made EUR 10 Million equity investment in Biotie and the parties amend the Selincro licensing agreement regarding territories outside the EU and US
03/08/2012 SER Biotie Interim report 1 January - 30 June 2012
03/08/2012 SER Biotie renews SEDA agreement with YA Global, securing committed standby equity of up to 20 million euro
05/07/2012 SER Biotie Completes Enrollment in Phase 2b Trial of Tozadenant in Parkinson's Disease
26/06/2012 SER Biotie announces Roche has decided to not exercise its rights to SYN120, a novel 5-HT6 antagonist for cognitive disorders
06/06/2012 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
04/05/2012 SER Biotie Interim report 1 January - 31 March 2012
02/05/2012 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
02/05/2012 SER Change in the Board of Directors
24/04/2012 SER Biotie and Seikagaku agree to end License Agreement on Biotie's VAP-1 antibody program
02/04/2012 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
29/03/2012 SER RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD
08/03/2012 SER Biotie's Stock Exchange Releases published in 2011
08/03/2012 SER Biotie's Annual Financial Report and Corporate Governance Statement 2011 published
05/03/2012 SER Data presented at the 2012 European Congress of Psychiatry showing that Selincro(TM) reduces total alcohol consumption by two-thirds on average after six months of treatment
01/03/2012 SER Biotie Successfully Completes Imaging Study with SYN120
24/02/2012 SER INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
24/02/2012 SER Biotie Therapies Corp. financial statement release 1 January - 31 December 2011
13/02/2012 SER Panu Miettinen appointed Chief Financial Officer of Biotie
04/01/2012 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
21/12/2011 SER Biotie's partner Lundbeck submits European Marketing Authorization Application for Selincro(TM) (nalmefene)
13/12/2011 SER US National Institute on Drug Abuse (NIDA) to Conduct Clinical Study on Biotie's Nepicastat in Cocaine Dependence
07/12/2011 SER The Board of Directors of Biotie Therapies Corp. Decided on Incentive Plans for Employees
02/12/2011 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
28/11/2011 SER Biotie's loan obligations to Tekes reduced by EUR 2.2 million
23/11/2011 SER Biotie provides UCB partnership update on SYN118
04/11/2011 SER Biotie Therapies Corp. Interim report 1 January - 30 September 2011
04/11/2011 SER Biotie Updates Outlook - Non-cash Impairment Charge for SYN118
04/11/2011 SER Biotie's Financial Information in 2012
28/10/2011 SER Biotie Terminates the Agreement to Acquire Newron
21/10/2011 SER Biotie informed that Merck Serono is returning full global rights for safinamide to Newron
05/10/2011 SER Notice to Biotie shareholders on registration of merger plan and documents available for review
27/09/2011 SER Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company Focused on Central Nervous System Drug Development
02/09/2011 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
01/09/2011 SER New interim CFO in Biotie
05/08/2011 SER Biotie Therapies Corp. Interim report 1 January - 30 June 2011
03/08/2011 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
28/07/2011 SER Correction to Biotie Therapies Corp. interim report for January - March 2011
26/07/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act regarding changes in number of votes
25/07/2011 SER Biotie Advances Clinical Program for SYN120 with Imaging Study at Johns Hopkins Center of Excellence
05/07/2011 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
15/06/2011 SER Biotie Announces Completion of Phase 3 Program with Nalmefene in Alcohol Dependence; European Marketing Authorization Application (MAA) expected by the end of 2011
06/06/2011 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
24/05/2011 SER Biotie announces topline data from an exploratory phase 2a study with SYN118 in Parkinson's disease
13/05/2011 SER Biotie Therapies Corp. interim report 1 January - 31 March 2011
06/05/2011 SER RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
07/04/2011 SER Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease
05/04/2011 SER INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
25/03/2011 SER Biotie's Stock Exchange Releases published in 2010
25/03/2011 SER Biotie's Annual Financial Report and Corporate Governance Statement 2010 published
25/03/2011 SER Biotie Therapies Corp. financial statement release 1 January - 31 December 2010
22/03/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
18/03/2011 SER New Biotie shares and increase of share capital registered with the trade register
17/03/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
15/03/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
11/03/2011 SER Biotie raises EUR 27 million from institutional and strategic investors
07/02/2011 SER Changes in Biotie's Financial Information in 2011
07/02/2011 SER Organizational meeting of the Board of Directors of Biotie Therapies Corp.
07/02/2011 SER Amendment to Biotie Therapies Corp. Articles of Association registered
04/02/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
03/02/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
03/02/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
03/02/2011 SER New Biotie Therapies Corp. shares and increase in share capital registered with the trade register
02/02/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
02/02/2011 SER The acquisition of Synosia Therapeutics Holding AG completed
01/02/2011 SER A listing prospectus concerning listing of new shares in Biotie Therapies Corp. has been published
01/02/2011 SER Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp. held on 1 February 2011
19/01/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
13/01/2011 SER Share capital increase registered with the trade register
12/01/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
11/01/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
10/01/2011 SER Biotie and Synosia to Combine to Create a Leading CNS Development Company, Conference Call Tuesday, 11 January, 3:00 p.m. Central European Time
10/01/2011 SER INVITATION TO THE EXTRAORDINARY GENERAL MEETING OF BIOTIE THERAPIES CORP.
03/01/2011 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
03/01/2011 SER Biotie Announces Positive Results from First Two Phase III Studies with Nalmefene in Alcohol Dependence
30/12/2010 SER Biotie's Financial Information in 2011
22/12/2010 SER Biotie's employee co-determination process concluded - restructuring complete
08/12/2010 SER Directed offer of treasury shares in Biotie Therapies Corp. pursuant to Standby Equity Distribution Agreement
03/12/2010 SER Share capital increase registered with the trade register
22/11/2010 SER Directed offer of treasury shares in Biotie Therapies Corp. pursuant to Standby Equity Distribution Agreement
29/10/2010 SER Biotie Therapies interim report: January - September 30, 2010
29/10/2010 SER Biotie and Roche conclude research and option agreement for SSAO inhibitors
29/10/2010 SER Biotie Announces Restructuring Plan; Future Focus Exclusively on Clinical Development; Conference Call Today
26/10/2010 SER New Biotie Therapies Corp. shares registered with the trade register
25/10/2010 SER A prospectus concerning Biotie Therapies Corp.'s issue of shares to the company itself without consideration has been published
25/10/2010 SER Biotie Therapies Corp.'s share issue to the company itself without consideration
25/10/2010 SER Correction to Biotie Therapies Corp. interim report for January - June 2010
15/10/2010 SER Biotie regains rights to develop PDE10 inhibitors for CNS disorders
14/09/2010 SER Biotie completes Phase I with VAP-1 antibody - BTT-1023 continues to demonstrate favourable safety profile
26/08/2010 SER Directed issue of shares in Biotie Therapies Corp. pursuant to Standby Equity Distribution Agreement
11/08/2010 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
06/08/2010 SER Biotie Therapies interim report: January - June 2010
07/05/2010 SER Biotie Therapies interim report: January - March 2010
26/04/2010 SER Biotie reports positive top-line data from clinical study with its third generation oral PDE4 inhibitor - ELB353 is well tolerated and shows clear pharmacological activity
22/04/2010 SER Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory disease
15/04/2010 SER Resolutions of the Annual General Meeting of Biotie Therapies Corp.
07/04/2010 SER Revised proposal from the Board's Nomination and Remuneration Committee to the Annual General Meeting of shareholders
17/03/2010 SER Invitation to The Annual General Meeting of Biotie Therapies Corp.
15/03/2010 SER Biotie's Stock Exchange Releases published in 2009
15/03/2010 SER Biotie's Annual Report 2009 and Corporate Governance Statement have been published
10/03/2010 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act relating to decrease in holdings
09/03/2010 SER Biotie Provides Update on Pfizer Research Collaboration
26/02/2010 SER Biotie Therapies Corp. financial statement release January 1 - December 31, 2009
23/02/2010 SER Biotie will publish its Financial Statement Release for 1 January - 31 December 2009 on Friday, 26 February 2010 at 9.00 a.m. Finnish time
19/01/2010 SER Biotie reports positive top-line data from clinical study with VAP-1 antibody in rheumatoid arthritis patients - BTT-1023 is well tolerated and shows signals of therapeutic activity
13/01/2010 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act relating to decrease in holdings
18/12/2009 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act relating to decrease in holdings
18/12/2009 SER Biotie´s Financial Information in 2010
14/12/2009 SER New Biotie shares and increase of share capital registered with the trade register
10/12/2009 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
08/12/2009 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
07/12/2009 SER Biotie raises EUR 7.2 million - directed issue of new shares in Biotie Therapies Corp. more than two times oversubscribed
04/12/2009 SER Directed issue of new shares in Biotie Therapies Corp. to institutional investors
29/10/2009 SER Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp.
23/10/2009 SER Biotie Therapies Corp. interim report January 1 - September 30, 2009
23/10/2009 SER Biotie secures committed standby equity up to 20 million euro
28/09/2009 SER Peter Fellner nominated to be elected to Biotie's Board of Directors
28/09/2009 SER Invitation to the Extraordinary General Meeting of Biotie Therapies Corp.
22/09/2009 SER Biotie signs an LP market making agreement with Nordea
14/09/2009 SER Biotie starts clinical study with phosphodiesterase 4 inhibitor ELB353
04/09/2009 PR Biotie Therapies to present at Rodman & Renshaw Annual Healthcare Conference
28/08/2009 SER Biotie Reaches Milestone in Wyeth Collaboration
07/08/2009 SER Biotie Therapies Corp. interim report January 1 - June 30, 2009
23/07/2009 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
29/05/2009 SER Resolutions of The Annual General Meeting of Biotie Therapies Corp.
20/05/2009 PR Biotie Names Chris Piggott as Chief Business Officer
15/05/2009 SER Biotie Therapies Corp. interim report January 1 - March 31, 2009
27/04/2009 SER Biotie Therapies Corp. Annual Report 2008 published
27/04/2009 SER The Board of Directors of Biotie Therapies Corp. decided on the issuance of option rights
27/04/2009 SER Invitation to The Annual General Meeting of Biotie Therapies Corp.
27/03/2009 SER Biotie's Annual Financial Report 2008 published
27/03/2009 SER Biotie Therapies Corp. Financial Statement Release January 1 - December 31, 2008
27/03/2009 SER Clinical study started with Biotie's proprietary VAP-1 antibody in psoriasis patients
12/03/2009 SER Nalmefene North-American rights acquired by Lundbeck
17/02/2009 SER Clinical study started with VAP-1 antibody in rheumatoid arthritis patients
06/02/2009 PR Biotie to present at The 11th Annual BIO CEO & Investor Conference in New York
03/02/2009 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
30/12/2008 SER Biotie's Financial Information in 2009
15/12/2008 SER Lundbeck announces start of new phase III clinical trials with nalmefene
17/11/2008 SER Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
14/11/2008 SER The acquisition of the pharmaceutical development company elbion GmbH completed
14/11/2008 SER Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp. held on November 14, 2008
12/11/2008 SER Biotie Therapies Corp. has published a listing prospectus
07/11/2008 PR Biotie to present at The Rodman & Renshaw 10th Annual Healthcare Conference, in New York, NY
24/10/2008 PR Biotie of Turku, Finland to acquire neurology and immunology focussed pharmaceutical company elbion GmbH
24/10/2008 SER Invitation to The Extraordinary General Meeting of Biotie Therapies Corp.
24/10/2008 SER Biotie to acquire CNS and inflammation specialist elbion GmbH
24/10/2008 SER Interim Report on Biotie Therapies Corp. January 1 - September 30, 2008
08/08/2008 SER Interim Report on Biotie Therapies Corp. January 1 - June 30, 2008
18/06/2008 SER Biotie's VAP-1 antibody program to proceed to clinical studies in rheumatoid arthritis and psoriasis patients
16/05/2008 PR Biotie to present at The Rodman & Renshaw 5th Annual Global Healthcare Conference
25/04/2008 SER Interim Report on Biotie Therapies Corp. January 1 - March 31, 2008
28/03/2008 SER Resolutions of the Annual General Meeting of Biotie Therapies Corp. held on March 28, 2008
26/03/2008 SER Addition to the Proposal to the Biotie Therapies Corp. Annual General Meeting convening on March 28, 2008
14/03/2008 SER Biotie Therapies Corp. Annual Report and Annual Summary 2007 published
29/02/2008 SER Invitation to the Annual General Meeting of Biotie Therapies Corp.
07/02/2008 PR Biotie to present at the 10th Annual BIO CEO & Investor Conference in New York
25/01/2008 SER Biotie Therapies Corp. Financial Statements Release January 1 - December 31, 2007
24/01/2008 SER Notification according to Chapter 2, Section 10 of the Securities Markets Act
07/01/2008 SER Tekes finances Biotie's Thrombosis program with EUR 1.7 million
02/01/2008 SER Nalmefene United Kingdom and Ireland rights acquired by Lundbeck
12/11/2007 SER Biotie's financial information in 2008
02/11/2007 PR BIOTIE TO PRESENT AT THE RODMAN & RENSHAW 9TH ANNUAL HEALTHCARE CONFERENCE IN NEW YORK
26/10/2007 SER BIOTIE ARRANGES A CAPITAL MARKETS DAY ON MONDAY 29TH OCTOBER, 2007
26/10/2007 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - SEPTEMBER 30, 2007
25/09/2007 SER BIOTIE'S VAP-1 ANTIBODY ENTERS CLINICAL DEVELOPMENT PHASE
10/08/2007 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - JUNE 30, 2007
28/06/2007 SER BIOTIE WITHDRAWS NALMEFENE NATIONAL MARKETING AUTHORISATION APPLICATION IN THE UK TO ENABLE A CENTRALISED EU-WIDE REGISTRATION PROCEDURE
21/06/2007 SER SCIENTIFIC PAPER ON NALMEFENE IN THE TREATMENT OF ALCOHOLISM
23/05/2007 SER BIOTIE REVISES OUTLOOK FOR 2007
23/05/2007 SER BIOTIE-LUNDBECK NALMEFENE LICENSE ENTERS INTO FORCE
11/05/2007 SER SUBSCRIPTION OF SHARES IN BIOTIE PURSUANT TO A CONVERTIBLE LOAN
30/04/2007 SER SUBSCRIPTION OF SHARES IN BIOTIE ON THE BASIS OF OPTION RIGHTS
27/04/2007 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - MARCH 31, 2007
05/04/2007 SER NOTIFICATION UNDER CHAPTER 2, SECTION 10 OF THE FINNISH SECURITIES MARKET ACT REGARDING CHANGE IN HOLDINGS
02/04/2007 SER SUBSCRIPTION OF SHARES IN BIOTIE PURSUANT TO A CONVERTIBLE LOAN
02/04/2007 SER NOTIFICATION OF CHANGE IN HOLDINGS UNDER CHAPTER 2, SECTION 10 OF THE FINNISH SECURITIES MARKET ACT
28/03/2007 SER RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. HELD ON 28 MARCH 2007
16/03/2007 SER BIOTIE THERAPIES CORP. ANNUAL REPORT AND ANNUAL SUMMARY 2006 PUBLISHED
08/03/2007 SER INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
26/01/2007 SER CORRECTION TO BIOTIE THERAPIES CORP. ENGLISH LANGUAGE FINANCIAL STATEMENT REPORT FOR THE PERIOD JANUARY 1 - DECEMBER 31, 2006
26/01/2007 SER BIOTIE THERAPIES CORP. FINANCIAL STATEMENTS RELEASE JANUARY 1 - DECEMBER 31, 2006
09/01/2007 SER NOTIFICATION UNDER CHAPTER 2, SECTION 10 OF THE FINNISH SECURITIES MARKET ACT REGARDING A CHANGE IN HOLDINGS
28/12/2006 SER BIOTIE'S FINANCIAL INFORMATION IN 2007
21/12/2006 SER NOTIFICATION OF CHANGE IN HOLDINGS UNDER CHAPTER 2, SECTION 10 OF THE FINNISH SECURITIES MARKET ACT
20/12/2006 SER BIOTIE RAISED EUR 18.8 MILLION NEW CAPITAL IN THE COMBINED INSTITUTIONAL AND SHAREHOLDER OFFERING
08/12/2006 SER BIOTIE SUPPLEMENTS THE OFFERING CIRCULAR PUBLISHED ON 1 DECEMBER 2006
08/12/2006 SER NOTIFICATION OF THE CHANGE IN HOLDINGS UNDER CHAPTER 2, SECTION 10 OF THE FINNISH SECURITIES MARKET ACT
07/12/2006 SER NOTIFICATION UNDER CHAPTER 2, SECTION 10 OF THE FINNISH SECURITIES MARKET ACT REGARDING CHANGE IN HOLDINGS
05/12/2006 SER BIOTIE LICENSING PARTNER SOMAXON REPORTS RESULTS FROM A CLINICAL TRIAL OF NALMEFENE IN PATHOLOGICAL GAMBLING
01/12/2006 SER NOTIFICATION UNDER CHAPTER 2, SECTION 10 OF THE FINNISH SECURITIES MARKET ACT REGARDING CHANGE IN HOLDINGS
30/11/2006 SER SUBSCRIPTIONS IN THE OFFERING OF BIOTIE THERAPIES CORP.
28/11/2006 SER RESOLUTIONS OF THE EXTRAORDINARY GENERAL MEETING OF BIOTIE THERAPIES CORP. ON 28 NOVEMBER 2006
27/11/2006 SER LUNDBECK AND BIOTIE SIGN AGREEMENT FOR NALMEFENE
24/11/2006 SER BIOTIE AND ROCHE SIGN AGREEMENT FOR VAP-1 ANTIBODY PROGRAM
21/11/2006 SER PROPOSALS OF THE BOARD OF DIRECTORS OF BIOTIE THERAPIES CORP. TO THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS CONVENING ON 28 NOVEMBER 2006 AND THE SUBMISSION OF MARKETING AUTHORISATION APPLICATION REGARDING NALMEFENE
01/11/2006 SER BIOTIE TO PRESENT AT THE 8TH ANNUAL RODMAN & RENSHAW HEALTHCARE CONFERENCE
27/10/2006 SER NOTICE PURSUANT TO CHAPTER 2, SECTION 10 OF THE SECURITIES MARKET ACT
27/10/2006 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - SEPTEMBER 30, 2006
27/10/2006 SER BIOTIE CONVENES EXTRAORDINARY GENERAL MEETING TO RESOLVE ON MEASURES TO STRENGTHEN THE COMPANY'S EQUITY, THE SUBSCRIPTION COMMITMENTS OF THE PLANNED SHARE ISSUE
27/10/2006 SER BIOTIE SIGNS FURTHER NALMEFENE MARKETING AGREEMENTS, IS SUBMITTING MAA
11/08/2006 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - JUNE 30, 2006
27/07/2006 SER SOMAXON PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM A PILOT PHASE 2 STUDY OF ORAL NALMEFENE IN SMOKING CESSATION
30/06/2006 SER CHANGE IN BIOTIE MANAGEMENT
28/06/2006 SER SUBSCRIPTIONS OF BIOTIE THERAPIES CORP.'S OPTION SCHEME 2006 HAVE BEEN APPROVED
11/05/2006 SER BIOTIE TO PRESENT AT THE 3RD ANNUAL RODMAN & RENSHAW GLOBAL HEALTHCARE CONFERENCE IN MONTE CARLO
28/04/2006 SER BIOTIE TO SUBMIT MAA FOR ORAL NALMEFENE AND SIGNS FIRST MARKETING AGREEMENT IN EUROPE
27/04/2006 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - MARCH 31, 2006
30/03/2006 SER THE RESOLUTIONS OF ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. WHICH CONVENED ON 30 MARCH 2006
23/03/2006 SER BIOTIE THERAPIES CORP. ANNUAL REPORT 2005 PUBLISHED
09/03/2006 SER INVITATION TO THE ANNUAL GENERAL MEETING
03/03/2006 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP. IN 2006
01/03/2006 SER BIOTIE THERAPIES CORP. REVISED OUTLOOK FOR 2006
27/01/2006 SER BIOTIE THERAPIES CORP. FINANCIAL STATEMENTS RELEASE JANUARY 1 - DECEMBER 31, 2005
27/12/2005 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP.IN 2006
21/11/2005 SER THE NATIONAL TECHNOLOGY AGENCY (TEKES) FINANCES BIOTIE'S VAP-1 MONOCLONAL ANTIBODY PROGRAM WITH EUR 2.5 MILLION
27/10/2005 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - SEPTEMBER 30, 2005
17/10/2005 SER BIOTIE AND SANOFI-AVENTIS HAVE AGREED NOT TO RENEW THE OPTION AGREEMENT
12/08/2005 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - JUNE 30, 2005
22/06/2005 SER FINAL SUBSCRIPTIONS OF THE OFFERING OF BIOTIE THERAPIES CORP.
17/06/2005 SER NOTICE PURSUANT TO THE FINNISH SECURITIES MARKET ACT, CHAPTER 2, SECTION 10 REGARDING CHANGE IN OWNERSHIP
15/06/2005 SER SUBSCRIBTIONS IN THE OFFERING OF BIOTIE THERAPIES CORP.
02/06/2005 SER BIOTIE SUPPLEMENTS ITS OFFERING CIRCULAR - SUBSCRIPTION COMMITMENTS RECEIVED FOR 53,2 % OF SHARES OFFERED
31/05/2005 SER SUBSCRIPTION COMMITMENTS RELATED TO THE OFFERING OF BIOTIE THERAPIES CORP.
30/05/2005 SER THE OFFERING CIRCULAR OF BIOTIE THERAPIES CORP. AVAILABLE
25/05/2005 SER THE RESOLUTIONS OF THE EXTRAORDINARY GENERAL MEETING OF BIOTIE THERAPIES CORP. WHICH CONVENED ON 25 MAY 2005
25/05/2005 SER TIMO VEROMAA APPOINTED PRESIDENT AND CEO OF BIOTIE THERAPIES CORP.
03/05/2005 SER BIOTIE THERAPIES CORP. STRENGTHENS ITS FINANCIAL POSITION
03/05/2005 SER INTERIM REPORT ON BIOTIE THERAPIES CORP.JANUARY 1 - MARCH 31, 2005
06/04/2005 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP. IN 2005
30/03/2005 SER BIOTIE THERAPIES OYJ: ADOPTION OF INTERNATIONAL FINANCIAL REPORTING STANDARDS
30/03/2005 SER THE RESOLUTIONS OF ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. WHICH CONVENED ON 30 MARCH 2005
30/03/2005 SER BIOTIE AND SANOFI-AVENTIS HAVE AGREED TO NEGOTIATE AN EXTENSION COVERING THE RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT TO DEVELOP A NEW HEPARIN-LIKE DRUG FOR BLOOD COAGULATION DISORDERS
14/03/2005 SER BIOTIE THERAPIES CORP.'S ANNUAL REPORT 2004 PUBLISHED
23/02/2005 SER SUBSCRIPTION OF BIOTIE'S SHARES AND INCREASE OF SHARE CAPITAL ON THE BASIS OF OPTION RIGHTS
08/02/2005 SER BIOTIE THERAPIES OYJ: INVITATION TO THE ANNUAL GENERAL MEETING
27/01/2005 SER BIOTIE THERAPIES CORP. FINANCIAL STATEMENTS RELEASE JANUARY 1 - DECEMBER 31, 2004
12/01/2005 SER BIOTIE IN-LICENSES A POTENTIAL ORAL TNF-ALFA INHIBITOR COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES
29/12/2004 SER SUBSCRIPTION OF BIOTIE'S SHARES AND INCREASE OF SHARE CAPITAL ON THE BASIS OF OPTION RIGHTS
27/12/2004 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP.IN 2005
20/12/2004 SER ROCHE AND BIOTIE COLLABORATE ON SMALL MOLECULE VAP-1 INHIBITOR PROGRAM
17/11/2004 SER THE NATIONAL TECHNOLOGY AGENCY (TEKES) FINANCES BIOTIE'S VAP-1 SSAO SMALL MOLECULE INHIBITOR PROGRAM WITH EUR 3.3 MILLION
12/11/2004 SER BIOTIE ENTERS INTO A LICENSING AGREEMENT WITH SOMAXON PHARMACEUTICALS FOR THE NORTH AMERICAN RIGHTS TO NALMEFENE
10/11/2004 SER CORRECTION OF INFORMATION RELATING TO LICENSING AGREEMENT
22/10/2004 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - SEPTEMBER 30, 2004
08/09/2004 SER SUBSCRIPTION OF BIOTIE'S SHARES AND INCREASE OF SHARE CAPITAL ON THE BASIS OF OPTION RIGHTS
19/08/2004 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - JUNE 30, 2004
20/07/2004 SER BIOTIE SIGNS A COOPERATION AND OPTION AGREEMENT WITH SOMAXON PHARMACEUTICALS INC. FOR THE NORTH AMERICAN RIGHTS TO NALMEFENE FOR THE TREATMENT OF IMPULSE CONTROL DISORDERS.
05/07/2004 SER THE NATIONAL TECHNOLOGY AGENCY (TEKES) FINANCES BIOTIE'S INTEGRIN PROJECT WITH EUR 1.4 MILLION
15/06/2004 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP.IN 2004
10/06/2004 SER SUBSCRIPTIONS OF BIOTIE THERAPIES CORP.'S CONVERTIBLE CAPITAL LOANS OF 25 MARCH 2004 AND SUBSCRIPTIONS OF OPTION SCHEME 2004 HAVE BEEN APPROVED
23/04/2004 SER INTERIM REPORT ON BIOTIE THERAPIES CORP.JANUARY 1 - MARCH 31, 2004
25/03/2004 SER THE RESOLUTIONS OF ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. 25 March 2004
24/03/2004 SER THE REQUEST FOR SPECIAL AUDIT REJECTED
24/03/2004 SER BIOTIE REACHES FIRST MILESTONE IN THE BIOTIE-AVENTIS CO-OPERATION AGREEMENT SIGNED ON MARCH 9, 2004
23/03/2004 SER BIOTIE THERAPIES CORP.'S ANNUAL REPORT 2003 PUBLISHED
17/03/2004 SER PROPOSALS OF THE BOARD OF DIRECTORS TO THE ANNUAL GENERAL MEETING CONVENING ON 25 MARCH 2004
09/03/2004 SER BIOTIE THERAPIES SIGNS RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT WITH AVENTIS TO DEVELOP NEW HEPARIN-LIKE DRUG FOR BLOOD COAGULATION DISORDERS
05/03/2004 SER INVITATION TO THE ANNUAL GENERAL MEETING
06/02/2004 SER SUBSCRIPTION OF BIOTIE'S SHARES AND INCREASE OF SHARE CAPITAL ON THE BASIS OF OPTION RIGHTS
29/01/2004 SER BIOTIE THERAPIES CORP. FINANLIZES CO-DETERMINATION PROCEDURE CONCERNING IT'S UNIT IN VIIKKI
28/01/2004 SER BIOTIE THERAPIES CORP. FINANCIAL STATEMENTS RELEASE JANUARY 1 - DECEMBER 31, 2003
19/01/2004 SER BIOTIE THERAPIES CORP. TO FOCUS ITS OPERATIONS TO TURKU
14/01/2004 SER DECISION OF THE BOARD OF DIRECTORS TO ISSUE A NEW OPTION SCHEME
19/12/2003 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP.IN 2004
28/10/2003 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - SEPTEMBER 30, 2003
08/10/2003 SER BIOTIE THERAPIES CORP.'S QUOTATION TO THE HELSINKI EXCHANGES NM LIST
02/10/2003 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP.IN 200
29/09/2003 SER BIOTIE THERAPIES CORP. IS APPLYING FOR THE TRANSFER OF ITS STOCK QUOTATION TO THE HELSINKI EXCHANGES NM-LIST
07/08/2003 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - JUNE 30, 2003
23/07/2003 SER BIOTIE INALCO HAVE AGREED ON THE CONTINUATION OF THE BIOHEPARINE-PROJECT
15/07/2003 SER BIOTIE´S AGREEMENTS RELATING TO BIOHEPARIN PROJECTS
04/07/2003 SER LISENCING AGREEMENT WITH SEIKAGAKU CORPORATION ENTERED INTO FORCE
26/06/2003 SER BIOTIE THERAPIES CORP.'S NOTIFICATION OF A CHANGE IN SHAREHOLDINGS IN ACCORDANCE WITH SECTION 2, CHAPTER 10 OF THE FINNISH SECURITIES MARKET ACT
25/06/2003 SER FINAL SUBSCRIPTIONS OF BIOTIE THERAPIES CORP. SHARE ISSUE
25/06/2003 SER BIOTIE THERAPIES CORP.'S NOTIFICATION OF A CHANGE IN SHAREHOLDINGS IN ACCORDANCE WITH SECTION 2, CHAPTER 10 OF THE FINNISH SECURITIES MARKET ACT
23/06/2003 SER SUBSCRIBTIONS IN BIOTIE THERAPIES CORP. SHARE ISSUE
19/06/2003 SER EXTRAORDINADY GENERAL MEETING OF BIOTIE THERAPIES CORP. OF 19 JUNE 2003 AND SUBSCRIPTIONS OF BIOTIE THERAPIES CORP. SHARE ISSUE
03/06/2003 SER LISTING PARTICULARS OF BIOTIE THERAPIES CORP. ISSUE OF NEW SHARES AVAILABLE
02/06/2003 SER THE CO-DETERMINATION PROCEDURE AT BIOTIE THERAPIES COMPLETED
30/05/2003 SER RESULTS FROM A PHASE II CLINICAL STUDY SUGGEST NALMEFENE EFFECTIVE IN THE TREATMENT OF PATHOLOGICAL GAMBLING
26/05/2003 SER THE RESOLUTIONS OF EXTRAORDINARY GENERAL MEETING OF BIOTIE THERAPIES CORP. 26 May 2003
26/05/2003 SER INFORMATION CONCERNING THE SHARE ISSUE OF BIOTIE THERAPIES CORP.
23/05/2003 SER BIOTIE ANNOUNCES RESULTS OF PHASE I TRIAL WITH VAPALIXIMAB IN HEALTHY VOLUNTEERS
19/05/2003 SER INVITATION TO THE EXTRAORDINARY GENERAL MEETING
15/05/2003 SER CLARIFICATION TO THE PROPOSAL OF THE BOARD OF DIRECTORS OF BIOTIE THERAPIES CORP. TO THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON 26 MAY 2003 CONCERNING THE INCREASE OF COMPANY'S SHARE CAPITAL BY NEW ISSUE
07/05/2003 SER BIOTIE THERAPIES OYJ: INVITATION TO THE EXTRAORDINARY GENERAL MEETING
06/05/2003 SER HANNU HANHIJÄRVI CONTINUES AS THE CHAIRMAN OF THE BOARD OF DIRECTORS
06/05/2003 SER SUBSCRIPTION OF BIOTIE'S SHARES AND INCREASE OF SHARE CAPITAL ON THE BASIS OF OPTION RIGHTS
05/05/2003 SER BIOTIE THERAPIES CORP. WILL TAKE ACTIONS TO ADAPT COSTS
02/05/2003 SER CLARIFICATION AND ADDITIONAL INFORMATION CONCERNING THE STOCK EXCHANGE RELEASE ON 28 APRIL 2003 ABOUT THE RESOLUTIONS OF THE NATIONAL TECHNOLOGY AGENCY (TEKES) TO GRANT ADDITIONAL FINANCING TO BIOTIE'S DRUG DEVELOPMENT PROGRAMS.
29/04/2003 SER THE RESOLUTIONS OF ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. 29 April 2003
28/04/2003 SER BIOTIE THERAPIES CORP. ENTERS INTO A LICENSING AGREEMENT COVERING THE VAP-1 ANTIBODY TECHNOLOGY WITH JAPANESE SEIKAGAKU CORPORATION
28/04/2003 SER THE NATIONAL TECHNOLOGY AGENCY (TEKES) FINANCES BIOTIE'S DRUG DEVELOPMENT PROJECTS WITH EUR 5.9 MILLION
28/04/2003 SER INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - MARCH 31, 2003
24/04/2003 SER BIOTIE REPORTS RESULTS OF TWO PHASE III CLINICAL STUDIES IN ALCOHOLISM AND ALCOHOL ABUSE
09/04/2003 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP.IN 2003
09/04/2003 SER NO ACTIVE NEGOTIATIONS BETWEEN BIOTIE THERAPIES AND ORION CORPORATION
07/04/2003 SER BIOTIE THERAPIES OYJ: INVITATION TO THE ANNUAL GENERAL MEETING
13/02/2003 SER CHANGE OF DATE OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
31/01/2003 SER BIOTIE THERAPIES CORP. SELLS ITS PROCESS DEVELOPMENT AND PRODUCTION UNIT
27/01/2003 SER BIOTIE THERAPIES CORP. (FORMER CONTRAL PHARMA UNTIL 31 OCT. 2002) FINANCIAL STATEMENTS RELEASE JANUARY 1 - DECEMBER 31, 2002
02/01/2003 SER BIOTIE THERAPIES CORP. HAS TRANSFERED CONTRAL CLINICS -BUSINESS TO A NEW COMPANY
20/12/2002 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP.IN 2003
28/11/2002 SER THE CO-DETERMINATION PROCEDURE AT BIOTIE THERAPIES COMPLETED
13/11/2002 SER KAUKO KURKELA, PRESIDENT AND CEO OF BIOTIE THERAPIES CORP., AND MARKKU JALKANEN, DEPUTY CEO OF BIOTIE THERAPIES CORP., HAVE RESIGNED
01/11/2002 SER JUHA JOUHKI'S AND HIS CONTROLLED ENTITIES THOMPROPERTIES LTD AND DREADNOUGHT FINANCE LTD HOLDING OF BIOTIE THERAPIES CORP. CAPITAL 6.60 PER CENT
31/10/2002 SER MERGER OF CONTRAL PHARMA CORPORATION, BIOTIE THERAPIES CORP. AND CARBION INC. COMPLETED.
29/10/2002 SER BIOTIE THERAPIES CORP. INTERIM REPORT 1 January - 30 September 2002, CONTRAL PHARMA LTD INTERIM REPORT 1 January - 30 September 2002 AND THE PRO-FORMA FIGURES OF THE MERGING COMPANY
28/10/2002 SER CHANGE OF DATE OF BIOTIE THERAPIES' JANUARY- SEPTEMBER INTERIM REPORT
25/10/2002 SER PROSPECTUS RELATED TO THE LISTING OF CONTRAL PHARMA CORPORATION PUBLISHED
22/10/2002 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP. IN 2002
16/10/2002 SER THE PRIVATE PLACEMENT OF CONTRAL PHARMA CORPORATION COMPLETED - SUBSCRIPTIONS FOR 15.1 MILLION EURO
15/10/2002 SER CONTRAL PHARMA CORPORATION (THE NEW BIOTIE THERAPIES CORP.) HAS FILED LISTING APPLICATION FOR PRE-LIST OF HELSINKI EXCHANGES
20/09/2002 SER BIOTIE THERAPIES, CONTRAL PHARMA AND CARBION WILL TAKE ACTIONS TO ADAPT COSTS
19/09/2002 SER BIOTIE STARTS CLINICAL TRIALS WITH MONOCLONAL ANTIBODY HUVAP
29/08/2002 SER BIOTIE THERAPIES CORPORATION INTERIM REPORT 1.1.-30.6.2002, CONTRAL PHARMA CORPORATION INTERIM REPORT 1.1.-30.6.2002 AND STRATEGY FOR THE COMBINED COMPANY
01/08/2002 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP. IN 2002
01/07/2002 SER A TOTAL OF 2,370,659 SHARES SUBCRIBED AT THE DIRECTED SHARE ISSUES OF CONTRAL PHARMA CORPORATION
17/06/2002 SER DECICIONS MADE IN THE EXTRAORDINARY GENERAL MEETINGS OF BIOTIE THERAPIES CORP., OY CONTRAL PHARMA LTD AND CARBION INC.
17/06/2002 SER CONTRAL PHARMA HAS RECEIVED SUBSCRIPTION COMMITMENTS AT WORTH OF 15 MEUR
10/06/2002 SER THE MERGER PROSPECTUS OF BIOTIE THERAPIES CORP., OY CONTRAL PHARMA LTD AND CARBION INC. PUBLISHED
07/06/2002 SER OY CONTRAL PHARMA LTD INTERIM REPORT, 1 January 2002 - 31 March 2002
29/05/2002 SER THE DISTRICT COURT OF HELSINKI'S DISMISSAL OF ORION'S CLAIM AGAINST BIOTIE THERAPOES' PATENTS BECOMES LEGALLY VALID AND NON-APPEALABLE
23/05/2002 SER THE NATIONAL TECHNOLOGY AGENCY (TEKES) FINANCES BIOTIE'S DRUG DEVELOPMENT PROJECTS WITH 3.6 MILLION EUROS
06/05/2002 SER THE RESOLUTIONS OF ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. 6 MAY 2002
06/05/2002 SER INTERIM REPORT OF BIOTIE THERAPIES CORP., JANUARY 1 - MARCH 31,2002
06/05/2002 SER THE DISTRICT COURT OF HELSINKI HAS DISMISSED ORION'S LEGAL ACTION IN THE CASE CONCERNING CERTAIN BIOTIE THERAPIES' PATENTS
06/05/2002 SER PROPOSALS BY BIOTIE THERAPIES CORP´S BOARD OF DIRECTORS AND INVITATION TO THE EXTRAORDINARY GENERAL MEETING
24/04/2002 SER THE DISTRICT COURT VERDICT ON THE TRIAL CONCERNING BIOTIE THERAPIES CORP'S CERTAIN PATENTS HAS BEEN POSTPONED
18/04/2002 SER INVITATION TO THE ANNUAL GENERAL MEETING
16/04/2002 SER BIOTIE THERAPIES, CONTRAL PHARMA AND CARBION TO MERGE AND FORM A STRONG DRUG DEVELOPMENT AND BIOTECHNOLOGY COMPANY
03/04/2002 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP. IN 2002
11/03/2002 SER BIOTIE THERAPIES CORP. BOARD OF DIRECTORS PROPOSALS FOR THE ANNUAL GENERAL MEETING
28/02/2002 SER THIRD PHASE I/II CLINICAL TRIAL IN VAP-1 ANTIBODY THERAPY PROGRAM COMPLETED: PRELIMINARY EVIDENCE OF EFFICACY ALSO IN PATIENTS WITH PSORIASIS
28/02/2002 SER THE TRIAL CONCERNING BIOTIE THERAPIES CORP'S CERTAIN PATENTS
24/01/2002 SER FINANCIAL STATEMENT BULLETIN OF BIOTIE THERAPIES CORP., JANUARY 1 - DECEMBER 31, 2001
11/12/2001 SER BIOTIE THERAPIES CORP. AND SHIMUZU PHARMACEUTICAL CO., LTD. ENTER INTO COLLABORATION AGREEMENT ON BIO
30/10/2001 SER INTERIM REPORT OF BIOTIE THERAPIES CORP., JANUARY 1 - SEPTEMBER 30, 2001
24/09/2001 SER BIOTIE BRINGS ITS HUMANISED VAP-1 MONOCLONAL ANTIBODY INTO CLINICAL DEVELOPMENT SOONER THAN EXPECTED
10/08/2001 SER INTERIM REPORT OF BIOTIE THERAPIES CORP., JANUARY 1 - JUNE 30, 2001
07/07/2001 SER FIRST CLINICAL STUDY RESULTS OF VAP-1 ANTIBODY THERAPY PROGRAM PRESENTED AT THE 11TH INTERNATIONAL CO
26/06/2001 SER THE OFFER PRICE IN COMBINED OFFERING IS IN EUR 6.80 PER OFFER SHARE
18/06/2001 SER THE NATIONAL TECHNOLOGY AGENCY (TEKES) FINANCES BIOTIE'S DRUG DEVELOPMENT PROJECTS WITH 3.4 MILLION EUROS
14/06/2001 SER RETAIL OFFERING OF BIOTIE THERAPIES CORP. SUSPENDED
07/06/2001 SER BIOTIE THERAPIES CORP. HAS FILED LISTING APPLICATION TO THE HELSINKI EXCHANGES ON 7 JUNE 2000 AND THE COMBINED OFFERING WILL COMMENCE ON 12 JUNE 2000
02/06/2001 SER BIOTIE THERAPIES CORP. BOARDS OF DIRECTORS PROPSALS FOR THE ANNUAL GENERAL MEETING.
21/05/2001 SER SIRPA AND MARKKU JALKANEN FOUNDATION TO RECEIVE 500 000 BIOTIE SHARES
09/05/2001 SER INTERIM REPORT OF BIOTIE THERAPIES CORP., JANUARY - MARCH 31, 2001
23/04/2001 SER SECOND STUDY OF PHASE I/II CLINICAL TRAIN IN VAP-1 ANTIBODY THERAPY PROGRAM COMPLETED
17/04/2001 SER FIRST CLINICAL STUDY RESULTS OF MONOLOGICAL ANTIBODY INHIBITING THE FUNCTION OF THE VAP-1 INFLAMMATION RECEPTOR
17/04/2001 SER SUBSCRIPTION OF BIOTIE'S SHARES AND INCREASE OF SHARE CAPITAL ON THE BASIS OF OPTION CERTIFICATES A AND B IN REALTION TO OPTION PROGRAM 2
07/04/2001 SER THE RESOLUTIONS OF ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. 6 APRIL 2001
06/04/2001 SER BIOHEPARIN EFFECTIVE IN PREVENTING THROMBOSIS IN ANIMAL STUDIES
16/03/2001 SER KEY ROLE OF VAP-1 INFLAMMATION RECEPTOR IN THE PATHOGENESIS OF INFLAMMATORY DISEASES REPORTED IN THE JOURNAL 'IMMUNITY' BY BIOTIE'S SCIENTIFIC PARTNER
06/02/2001 SER BIOTIE THERAPIES CORP. STOCK EXCHANGE BULLETIN 1(12) 6 FEBRUARY AT 12.00 FINANCIAL STATEMENT BULLETIN OF BIOTIE THERAPIES CORP., JANURAY 1 - DECEMBER 31, 2000
19/01/2001 SER SUBSCRIPTIONS OF OPTION RIGHTS
10/01/2001 SER NEW INTEGRIN ALPHA2-BLOCKERS ENTER BIOTIE THERAPIES' PRECLINICAL STUDY PHASE
29/12/2000 SER FINANCIAL INFORMATION OF BIOTIE THERAPIES CORP. IN 2001
07/08/2000 SER BIOTIE THERAPIES CORP. STRENGTHENS ITS MANAGEMENT
31/07/2000 SER STABILISATION PERIOD OF BIOTIE THERAPIES CORP. ENDS
30/06/2000 SER BIOTIE THERAPIES CORPORATION'S FINANCIAL REPORTS DURING 2000
29/06/2000 SER ANNOUNCEMENT ACCORDING TO CHAPTER 2 SECTION 10 OF THE SECURITIES MARKET ACT
29/06/2000 SER BIOTIE THERAPIES CORPORATION'S SHARE CAPITAL INCREASE REGISTERED AND STABILIZATION
28/06/2000 SER BIOTIE THERAPIES CORPORATION'S SHARE CAPITAL INCREASE REGISTERED
26/06/2000 SER THE OFFER PRICE IN COMBINED OFFERING IS EUR 6.80 PER OFFER SHARE
14/06/2000 SER RETAIL OFFERING OF BIOTIE THERAPIES CORP. SUSPENDED
25/05/2000 SER BIOTIE THERAPIES SEEKS LISTING ON THE NM LIST OF THE HELSINKI STOCK EXCHANGE